Research on Disease Mechanisms
- Milestone 2.A •
Create new research programs that use data-driven, systems-based approaches to integrate the study of fundamental biology of aging with neurobiology of aging…
- Milestone 2.B •
Establish new research programs that employ data-driven, systems-based approaches to understand the interaction between peripheral systems (in particular: immune, metabolic, microbiome) and the brain
- Milestone 2.C •
Create research programs on epigenetics to understand how genetic and environmental factors interact across the lifespan to influence brain aging…
- Milestone 2.D •
Create programs in basic, translational and clinical research aimed at comprehensive understanding of the impact of sex differences on the trajectories of brain aging…
- Milestone 2.E •
Create cross-disciplinary research programs aimed at understanding the integrative physiology of APOE…
- Milestone 2.F •
Create new research programs aimed at understanding the integrative physiology of circadian rhythms and sleep…
- Milestone 2.G •
Maximize the translational potential of genetics research by ensuring rapid and broad sharing of large-scale genetic/genomic data...
- Milestone 2.H •
Continue to support cross-disciplinary research to discover and understand disease mechanisms...
- Milestone 2.I •
Enable a system biology approach to decipher the complex role of the microbiome in brain aging and AD/ADRD...
- Milestone 2.J •
Expand research on the role of social and psychosocial factors, on AD risk and resilience to risk in ethnically and socioeconomically diverse populations...
- Milestone 2.K •
Create new research programs that use data-driven, network biology approaches aimed at understanding the (epi)genetics and complex biology of cognitive resilience...
- Milestone 2.M •
Develop LBD animal, cellular, and in vitro models that recapitulate key features, including clinical pathophysiologic heterogeneity to identify mechanistic candidates for interventions.
- Milestone 2.O •
Determine the molecular basis for C9ORF72 expansion-and GRN mutation-related neurodegeneration.
AD Related Dementias - Specific
- Milestone 2.L •
Promote basic and clinical research in multi-etiology dementia.
- Milestone 2.N •
Clarify the mechanism of tau pathogenesis and associated neurodegeneration.
- Milestone 2.P •
Determine the mechanism of TDP-43 and FUS pathogenesis and toxicity.
- Milestone 2.Q •
Encourage basic science research that investigates the impact of aging, AD pathology, and genes on peri- and para-vascular clearance mechanisms, the NVU, and cerebrovascular function.
- Milestone 2.R •
Encourage basic science research that investigates the impact of cerebrovascular risk factors/genes and atherosclerosis on AD-related neurodegeneration.
- Milestone 2.S •
Determine interrelationships among aging, cerebrovascular disease and risk factors, resilience factors, genetic variants, amyloid, tau, and neurodegeneration.
- Milestone 2.T •
Understanding the molecular, cellular and α-synuclein in the context of non-motor brain areas.
- Milestone 2.U •
Determine underlying pathobiologic and molecular mechanisms of cellular TDP-43 displacement, post-translational modifications such as phosphorylation, and pathology in pre-symptomatic and manifest
- Milestone 2.V •
Examine the pathologic phenotype(s) of TDP-43 pathology in asymptomatic persons and those with common dementias.
- Milestone 2.W •
Promote basic and clinical research examining the development and progression of TBI AD/ADRD neuropathologies and associated clinical symptoms.